{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:17:20Z","timestamp":1790648240990,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The clinically investigated rationale for <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.guidetopharmacology.org\/GRAC\/FamilyDisplayForward?familyId=740\">neprilysin<\/jats:ext-link> (NEP)\u2010inhibition by angiotensinreceptor\u2010NEPinhibitor (ARNi) therapy is to induce elevations in endogenous natriuretic peptides. NEP, however, cleaves a broad spectrum of substrates, which partially hold significant implications in heart failure with reduced ejection fraction (HFrEF). The effect of NEP inhibition on these peptides has not been investigated thoroughly. This study explored the response of <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=683\">adrenomedullin<\/jats:ext-link> (ADM) regulation to the initiation of ARNi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seventy\u2010four patients with stable HFrEF and initiation of ARNi were prospectively enrolled, 67 patients on continuous angiotensin\u2010converting\u2010enzyme inhibitor(ACEi)\/angiotensin\u2010receptor blocker (ARB) therapy served as control. Plasma bioactive\u2010ADM (bio\u2010ADM), mid\u2010regional\u2010pro\u2010ADM (MR\u2010proADM), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=4890\">B\u2010typenatriuretic peptide<\/jats:ext-link> (BNP) and N\u2010terminal\u2010pro\u2010BNP (NT\u2010proBNP) were determined at baseline, short\u2010term, 1\u2010year and 2\u2010year follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following ARNi initiation both bio\u2010ADM and MR\u2010proADM concentrations were significantly increased at early and long\u2010term follow up (bio\u2010ADM [pg\/mL]: 26.0 [interquartile range {IQR}: 17.7\u201337.5] <jats:italic>vs.<\/jats:italic> 50.8 [IQR: 36.5\u201378.1] <jats:italic>vs.<\/jats:italic> 54.6 [IQR: 42.0\u201397.1] <jats:italic>vs.<\/jats:italic> 57.4 [IQR: 48.5\u2013161.6]; MR\u2010proADM [nmol\/L]: 0.87 [IQR: 0.64\u20131.12] <jats:italic>vs.<\/jats:italic> 1.25 [IQR: 0.93\u20131.79] <jats:italic>vs.<\/jats:italic> 1.42 [IQR: 0.95\u20131.90] <jats:italic>vs.<\/jats:italic> 1.60 [IQR: 1.12\u20132.46], <jats:italic>P &lt;<\/jats:italic> .0001 for all). The ratios bio\u2010ADM\/MR\u2010proADM and BNP\/NT\u2010proBNP increased during ARNi\u2010therapy proving improved availability of bioactive peptides. The proportional increase of bio\u2010ADM markedly exceeded BNP increase. Patients converted to ARNi showed similar biomarker patterns irrespective of baseline renin\u2013angiotensin system blocker therapy, i.e. ACEi or ARB (<jats:italic>P &gt;<\/jats:italic> .05 for all), indicating that activation of the ADM\u2010axis arises particularly from NEPinhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The significant increase of MR\u2010proADM and bio\u2010ADM together with an elevated bioADM\/MR\u2010proADM ratio suggest both enhanced formation and reduced breakdown of bioactive ADM following the initiation of ARNi. Activation of the ADM\u2010axis represents a so far unrecognized effect of ARNi.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14442","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T14:44:08Z","timestamp":1593441848000},"page":"916-924","source":"Crossref","is-referenced-by-count":16,"title":["Increased concentrations of bioactive adrenomedullin subsequently to angiotensin\u2010receptor\/neprilysin\u2010inhibitor treatment in chronic systolic heart failure"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5836-7759","authenticated-orcid":false,"given":"Henrike","family":"Arfsten","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6219-6104","authenticated-orcid":false,"given":"Georg","family":"Goliasch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-4839","authenticated-orcid":false,"given":"Philipp E.","family":"Bartko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-7979","authenticated-orcid":false,"given":"Suriya","family":"Prausm\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-6491","authenticated-orcid":false,"given":"Georg","family":"Spinka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-2503","authenticated-orcid":false,"given":"Helmuth","family":"Haslacher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-5105","authenticated-orcid":false,"given":"Guido","family":"Strunk","sequence":"additional","affiliation":[{"name":"Complexity Research  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[{"name":"Sphingotec GmbH  Hennigsdorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7944-7363","authenticated-orcid":false,"given":"Martin","family":"H\u00fclsmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-4507","authenticated-orcid":false,"given":"Noemi","family":"Pavo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.060"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2017.08.006"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00622.x"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.08.65"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01428.x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp004"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1366"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1437"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.200"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1342"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.018"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.3789"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.799"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816121-00030"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfq031"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2168"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.10.033"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-016-0229-2"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc13731"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33495"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-02-0128"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000036603.61868.F9"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13655"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1693"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.1420.x"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000037132.90640.26"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.6.1983"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.12.021"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:49:42Z","timestamp":1693655382000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/bcp.14442"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14442","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]}}}